Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21)

The summary for the Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21)
	CFDA Number:	93.847
	CFDA Description:	Diabetes, Endocrinology and Metabolism Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Food and Nutrition Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-09-133
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Mar 17, 2009
	Creation Date:	Mar 17, 2009
	Original Closing Date for Applications:	May 07, 2012
	Current Closing Date for Applications:	May 07, 2012
	Archive Date:	Jun 07, 2012
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	$200,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: Purpose. This FOA, issued by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Office of Dietary Supplements (ODS) of the National Institutes of Health, encourages exploratory/developmental clinical research related to the prevention or treatment of diabetes, obesity and endocrine and genetic metabolic diseases. The Pilot and Feasibility Clinical Research Grants Program is designed to allow initiation of exploratory, short-term clinical studies, so that new ideas may be investigated without stringent requirements for preliminary data. The short-term studies should focus on research questions that are likely to have high clinical impact. They can include testing a new prevention strategy, a new intervention, or unique combinations of therapies. A high priority is the use of such studies to help stimulate the translation of promising research developments from the laboratory into clinical practice in diabetes, endocrine diseases and genetic metabolic diseases, including cystic fibrosis. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/pa-09-133.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Pediatric Centers of Excellence in Nephrology (P50); • Nutrition Obesity Research Centers (P30); • George M. OBrien Kidney Research Core Centers (P30); • Cooperative Study Group for Autoimmune Disease Prevention (U01); • Collaborative Interdisciplinary Team Science in NIDDK Research Areas (R24); • PROTEOMIC AND METABOLOMIC APPROACHES TO DIAGNOSE DIABETES AND PRE-DIABETES; • MOLECULAR THERAPY CORE CENTERS; • PILOT AND FEASIBILITY PROGRAM IN HUMAN ISLET BIOLOGY; • DIABETES ENDOCRINOLOGY RESEARCH CENTERS; • CYSTIC FIBROSIS RESEARCH AND TRANSLATION CORE CENTERS